Labcorp has announced that the FDA has approved its companion diagnostic for patients with advanced melanoma. This diagnostic specifically supports patients carrying certain BRAF variants.
Labcorp has announced that the FDA has approved its companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
Labcorp Holdings Inc. raised its outlook for the year after reporting second-quarter earnings that topped analyst estimates. The company cited strength in cancer tests and new genetic screenings as key factors contributing to this positive performance.